Glapp launched free in March 2026 and introduced paid tiers in June; reviewers, including self-identified beta testers, say most of what was free moved behind the new tier without grandfathering. It still leads the category on supply tracking, so weigh that against the paywall rather than writing it off. Veya is a provider-neutral tracker for iPhone, with reminders that repeat until you log the dose.
Why people are leaving Glapp
Glapp launched on iOS in March 2026, free and with no in-app purchases at all, and built a following in part through word of mouth and Reddit before it introduced paid tiers under the name "Glapp Max" that June. Its own reviewers, including people who describe themselves as beta testers who had contributed feedback while the app was free, report most of that previously-free functionality moving behind the new subscription without warning and without being grandfathered in. One reviewer says they received an email promising previously-free features would stay free, and that this did not turn out to be true.
This isn't a fringe complaint from a handful of angry one-star reviews. One of the reviews describing the change is a four-star rating with a body that reads as a clear refusal to pay for what used to be free: a mismatch worth noting, since it suggests even reviewers still rating the app fairly highly feel strongly about the change. We're reporting what reviewers say happened to them; we haven't tested the app ourselves, and we're not asserting why the change was made.
Separately, Glapp's support has told at least one reviewer that shots cannot be scheduled for specific weekdays, which rules out common twice-weekly regimens for anyone on a fixed schedule rather than a rolling one.
What is difficult to accept is that features and user data that existing users have been relying on are now locked behind a subscription. As one of the app's earliest users and a beta tester, I contributed feedback and data to help shape the product. It feels unfair that access to that same data is now restricted unless payment is made. My other concern is the lack of a proper export option... Overall, this change has significantly reduced my trust in the app, and I've decided to stop using it.
4-star rating despite a negative body about the new premium tier and a refusal to pay.
How naive of me to think that the Glapp folks would continue to make it available to us users who helped tweak and fine tune it in beta. I won't be buying it…
I'm having difficulty figuring out how to schedule shots. My schedule is every Tuesday and Friday. If you're only doing 1 shot / week, then this app is for you... Edit: Support team said I can't schedule shots for specific weekdays. 😓
What to check before you switch
We could not confirm, either way, whether Glapp currently offers a way to export your own data out of the app. The evidence we found on this point is mixed: reviewers and third-party material disagree. We're not stating it has no export, and we're checking directly before we publish that as a hard fact. If data portability matters to you, check inside the app yourself before you commit your history to it, and don't assume an importer elsewhere will substitute for an export you never took.
Where each app stands, on the dimensions we compared
This table covers logging, scheduling, food logging, syncing and provider-neutrality across Glapp and four alternatives, as of August 2026. It isn't exhaustive: it omits supply/vial tracking, split dosing and importing from another app, since Veya doesn't ship those, and it also omits data export, since whether Glapp currently has one is unresolved in our research and we won't render an unverified cell either way. "Unknown" means unverified, not absent.
| Feature | Veya | Glapp | Shotsy | Pokii | GlucoPal | MeAgain |
|---|---|---|---|---|---|---|
| Dose logging | Yes | Yes | Yes | Yes | Yes | Yes |
| Escalating reminders | Yes | Not verified | No | Not verified | Not verified | No |
| Estimated medication-level curve | No | Yes | Yes | Yes | Not verified | Yes |
| Food logging | No | Partial | Partial | Partial | Yes | Yes |
| Cross-device sync | Yes | Yes | Partial | Yes | Yes | No |
| Provider-neutral | Yes | Yes | Yes | Yes | Yes | No |
| Sells medication | No | No | No | No | No | Yes |
* Not verified means we could not confirm this either way from the app’s own published material. It does not mean the feature is absent.
Shotsy: an estimated medication-level curve
Shotsy offers an estimated medication-level curve covering a wider range of molecules than the other apps in this comparison, and reviewers describe it changing an actual dosing decision, not just recording one. Its own App Store version history documents CSV export as a shipped feature, which is worth knowing if data portability is what's pushing you off Glapp specifically.
An estimated curve like this is a model, not a measurement. How quickly someone clears a GLP-1 medication varies with body weight, height, metabolism and dose history, so the same estimate can be some way off for two people on an identical dose. Our own view is that a number shown with more precision than the underlying model supports isn't something you'd want to take to a prescriber as fact, which is why Veya's own record focuses on what was actually taken and when, rather than modelling what's left in the body.
Shotsy doesn't have Glapp's supply tracking, and it has its own history of paywalling previously-free features, so read its recent reviews before assuming it's paywall-proof.
What Shotsy does well: Estimated medication-level chart covering semaglutide, tirzepatide, liraglutide and dulaglutide. Supports CSV export.
The paid upgrade is worth it IMO so that you can to see a 100% personalized graph of your estimated medication levels — this is CRUCIAL if you suspect you are either a slow responder or a super responder, as you work with your provider to figure out the best dose for your body. This app helped me connect the dots and modify my dose & injection schedule when I realized I was a super responder.
Pokii: the thin client
Reviewers repeatedly describe choosing Pokii because they were able to use it without subscribing, though it publishes its own subscription tiers alongside an optional tip jar, worth checking directly if Glapp's new paywall is specifically what's driving you away.
It's a thinner client than Glapp by design, so if Glapp's supply tracking is why you chose it in the first place, weigh that trade-off carefully.
What Pokii does well: Covers retatrutide and custom medications. Native iPad app.
Does exactly what I wanted to do: track Wegovy injections, body measurements, and weight all in one place. You can also track water and nutrition which are added bonuses for me. Best part is I don't have to pay a monthly or yearly subscription. The app looks great- there are a few UI things that could be improved, like the option to manually enter data as opposed to using a slider or tapping things, the top-right utility menu isn't quite long enough to fit the contents… but those are mostly just visual, this app is functioning just as well if not better than the paid ones.
GlucoPal: no account, a genuinely usable free tier
GlucoPal requires no account to use at all, and reviewers who chose it describe a free tier that's genuinely usable on its own rather than a taster for a paid version: a different experience from Glapp's post-launch shift. It has the lowest minimum iOS requirement of any app in this comparison, so it's worth a look on older devices too.
It doesn't match Glapp's benchmarking against clinical-trial data, so it suits someone who wants the basics done simply rather than Glapp's fuller feature set.
What GlucoPal does well: Works without an account. Runs on older iPhones than the rest of the category.
I was trying to keep track of all those little cards I had torn off the boxes of Ozempic documenting that I had taken it and which leg I had given it in, and then I ran across this app. Thank you God! It has helped immensely! AND it has kept me from missing my injection more than once with its alerts.
MeAgain: real food logging, but its own paywall to weigh
MeAgain is the only app in this comparison with genuinely integrated food logging (photo, barcode and manual entry alongside fibre tracking), which reviewers say measurably changed how they eat. If Glapp's limited food logging is your real frustration, this is the closest thing to a single-app fix.
MeAgain reviewers repeatedly report being unable to use the app at all without subscribing, having first completed an onboarding questionnaire. It's the largest single complaint cluster we found anywhere in this category, though MeAgain's developer has publicly replied stating most features are in fact free. Going from one paywall frustration to another isn't necessarily an upgrade, so read MeAgain's own reviews before you commit.
What MeAgain does well: Integrated food logging with barcode scanning and fibre tracking. Apple Health integration.
Customer support and assistance from Rodrigo (a co-founder of MeAgain) was stellar. He really went above and beyond to ensure my issue was completely resolved... It has been very helpful to see the medication level estimates to be able to plan injections and meals around that.
What Glapp does well
Be fair to Glapp: its vial-level supply tracking, ordered by beyond-use date, is the single most-cited reason reviewers give for switching to it in the first place, and nothing else in this comparison matches it. It's also the only app here with a genuine Apple Watch app.
One reviewer describes a forced-update lockout that had dropped their rating to one star. After a direct developer reply, the issue was fixed and the reviewer revised their review to five stars the same day.
What Glapp does well: Vial-level supply tracking. Clinical-trial and peer benchmarking.
Revised from 1 star to 5 stars the same day, after a developer reply about the forced-update lockout.
This app has been great up until today. When I opened it, I was hit with a splash screen that completely locked me out unless I updated the app. That felt totally unnecessary. Feel free to suggest an update when one's available, but randomly locking users out just to force an update to the latest version is not the way to do it. Barring that, this is a 5 star app. For now, it's a 1. UPDATE— given the response from the dev, changing my review to 5.
Why are people leaving Glapp?
Glapp launched free in March 2026 and introduced paid tiers, "Glapp Max", that June. Its own reviewers, including some who describe themselves as beta testers, report most previously-free functionality moving behind that subscription without warning and without being grandfathered in. Separately, Glapp's support has told a reviewer that shots cannot be scheduled for specific weekdays.
Does Glapp let you export your data?
We could not confirm this either way from published material: the evidence is mixed between reviewer accounts and third-party sources. We're checking directly and will update this page once we have a clear answer, rather than stating a hard negative we can't yet stand behind.
What does Glapp do better than its rivals?
Its vial-level supply tracking is the standout feature in the category and the reason most reviewers cite for switching to it.
Did Glapp's paywall change come without warning?
We're not going to characterise the developers' motive: we can't know it, and reviewers' accounts of what changed and when are the verifiable part of this. What we can report is that the app launched free with no in-app purchases, introduced a paid tier roughly three months later, and that its own reviewers describe previously-free features moving behind that subscription without grandfathering.
What's the best alternative to Glapp?
It depends what's driving you away. If it's the paywall and you want the deepest medication-level modelling, Shotsy is the strongest option, with the caveat that it has its own history of paywalling features. If you'd rather not commit to a subscription, Pokii's reviewers repeatedly say they've used it without subscribing, alongside a separate optional tip jar. If you want the simplest possible app, GlucoPal needs no account.
Are Glapp's developers responsive to complaints?
Reviewers describe them that way in specific instances. One reviewer reports a forced-update lockout that had dropped their rating to one star, followed by a direct developer reply, after which the issue was fixed and the review was revised to five stars the same day. That doesn't resolve the separate paywall complaints, but it's a documented instance worth knowing about.